Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CorCap Efficacy Data Deemed Scant By Panel; Acorn Vows Not To Lose Heart

This article was originally published in The Gray Sheet

Executive Summary

Acorn Cardiovascular will work with FDA to address panel concerns with CorCap that arose during a June 22 meeting to review the ventricular support device

You may also be interested in...



Acorn Asks For More Help From Investors After FDA Panel Denies CorCap PMA

Acorn Cardiovascular says it will ask its current investors to fund a confirmatory trial of its CorCap Cardiac Support Device after an FDA advisory panel decided more research is needed before it could support premarket approval

Acorn Asks For More Help From Investors After FDA Panel Denies CorCap PMA

Acorn Cardiovascular says it will ask its current investors to fund a confirmatory trial of its CorCap Cardiac Support Device after an FDA advisory panel decided more research is needed before it could support premarket approval

CorCap gets thumbs-down

FDA's Medical Device Dispute Resolution Panel Dec. 15 voted 3-1 against approval of Acorn Cardiovascular's CorCap Cardiac Support Device, citing a lack of data to prove the device's benefits outweigh risks. The polyester mesh wrap, which envelops the heart to treat adults with dilated cardiomyopathy, received a negative review by an FDA advisory panel in 2005 (1"The Gray Sheet" June 27, 2005, p. 3). A 300-patient pivotal trial showed 38% of patients improved with CorCap versus 27% of controls, meeting its primary endpoint. However, FDA officials argued against approval, saying that a substantial amount of data collected early in the trial did not meet the agency's specifications. Acorn has spent $80 mil. developing the device, Richard Lunsford, Acorn CFO, told "The Gray Sheet." The privately held firm will now go back to its sponsors, including Johnson & Johnson, for funds to perform a confirmatory trial, he said...

Related Content

UsernamePublicRestriction

Register

MT022299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel